Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Triple Negative Breast Cancer Clinical Trials
Triple Negative Breast Cancer clinical trials are recruiting across 127 cities. Here are the cities with the most active studies:
Triple Negative Breast Cancer Trial Phases
46 research organizations are sponsoring triple negative breast cancer trials.
About Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.
Clinical trials are advancing new treatments for triple negative breast cancer. Currently, 62 studies are recruiting a combined 13,877 participants across the United States. Research is being conducted by 46 organizations including SWOG Cancer Research Network, Merck Sharp & Dohme LLC, Gilead Sciences and 43 others.
2026 Triple Negative Breast Cancer Research Landscape
As of July 2026, the triple negative breast cancer clinical trial landscape includes 62 actively recruiting studies across 127 cities in the United States. These studies are collectively seeking 13,877 participants, with an average enrollment target of 224 per study.
The research spans multiple phases of development: 28 studies are in PHASE2, 22 studies are in PHASE1, 7 studies are in PHASE3, 5 studies are in NA, 4 studies are in EARLY_PHASE1. The presence of Phase 3 trials indicates that some triple negative breast cancer treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 46 different organizations, including SWOG Cancer Research Network, Merck Sharp & Dohme LLC, Gilead Sciences, University of Kansas Medical Center, Jina Pharmaceuticals Inc., and 41 others. The large number of sponsors reflects significant research interest and investment in triple negative breast cancer treatment advancement.
Geographically, triple negative breast cancer trials are most concentrated in Los Angeles, California (11 trials); Atlanta, Georgia (8 trials); New Haven, Connecticut (6 trials); Tampa, Florida (6 trials); Boston, Massachusetts (6 trials) and 7 other cities.
Featured Triple Negative Breast Cancer Studies
Highlighted recruiting studies for triple negative breast cancer, selected by enrollment size and research scope.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinu...
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare...
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgica...
Frequently Asked Questions About Triple Negative Breast Cancer Clinical Trials
Are there triple negative breast cancer clinical trials near me?
Yes, there are 62 triple negative breast cancer clinical trials currently recruiting across 127+ cities in the United States, including Los Angeles, California; Atlanta, Georgia; New Haven, Connecticut. Browse the studies above to find one at a location convenient for you.
How do I join a triple negative breast cancer clinical trial?
To join a triple negative breast cancer clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are triple negative breast cancer clinical trials free?
Yes, participation in triple negative breast cancer clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of triple negative breast cancer treatments are being studied?
Current triple negative breast cancer clinical trials are testing a range of approaches across PHASE2 (28 studies), PHASE1 (22 studies), PHASE3 (7 studies), NA (5 studies), EARLY_PHASE1 (4 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 46 research organizations.
Is it safe to participate in triple negative breast cancer clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 15, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 15, 2026 · Data from ClinicalTrials.gov